Phase II study of cetuximab in mucinous peritoneal carcinomatosis

Eleni Andreopoulou(Cornell University), Andrew M. Lowy(UC San Diego Health System), David Mauro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Howard S. Höchster(Rutgers, The State University of New Jersey), Elliot Newman(Bristol-Myers Squibb (United States)), Franco M. Muggia(NYU Langone Health), Juliet Escalon(Bristol-Myers Squibb (United States)), C. Wojtaszek(Bristol-Myers Squibb (United States)), Andrea Downey(University of New Mexico), Malek M. Safa(Bristol-Myers Squibb (United States))
Journal of Clinical Oncology
June 20, 2006
10.1200/jco.2006.24.18_suppl.14020
Cited by 4

Related Papers

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391